Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: SB 223242; SB 223412; SB 223412A; Talnetant hydrochloride

Latest Information Update: 07 Feb 2008

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GlaxoSmithKline
  • Class Irritable bowel syndrome therapies
  • Mechanism of Action Neurokinin 3 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Schizophrenia
  • Discontinued Chronic obstructive pulmonary disease; Cough; Irritable bowel syndrome; Overactive bladder; Urinary incontinence

Most Recent Events

  • 30 May 2007 Data presented at the Digestive Disease Week-2007 (DDW-2007) have been added to the Digestive system disorders therapeutic trials section ,
  • 14 May 2007 Talnetant is still in phase II trials for schizophrenia in the US
  • 15 Dec 2005 Discontinued - Phase-II for Irritable bowel syndrome in United Kingdom (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top